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Summary
Background: The Norwegian Ministry of Health and Care Services initiated a project 
including experimental treatment for patients with health complaints attributed to 
amalgam restorations.
Objective: The aim was to evaluate changes of general health complaints in patients 
who participated in the project and had all amalgam restorations removed.
Methods: The project was designed as a prospective cohort study and organised 
by the Dental Biomaterials Adverse Reaction Unit in Bergen, Norway. The dental 
treatment was provided by the patient's local dentist. The main target group con-
sisted of patients with medically unexplained physical symptoms, attributed to dental 
amalgam restorations (Amalgam cohort). The primary comparison group consisted of 
patients with medically unexplained physical symptoms without attribution to dental 
amalgam restorations (MUPS cohort). Primary outcome was self-reported general 
health complaints (GHC index) at follow-up 12-months after completed amalgam 
removal.
Results: In the Amalgam cohort, a significant reduction of GHC index from 43.3 (SD 
17.8) at baseline to 30.5 (SD 14.4) at follow-up (mean reduction 12.8, SD 15.9; n = 32; 
P < .001) was observed. The change scores for GHC index indicated that the reduc-
tion of complaints was significantly higher (P = .004) in the Amalgam cohort com-
pared with the MUPS cohort (mean reduction 1.2, SD 12.3, n = 28). After adjustment 
for age, gender, education and baseline GHC index, the mean adjusted difference 
was −8.0 (95% confidence interval from −15.4 to −0.5; P = .036).
Conclusion: In a group of patients with medically unexplained physical symptoms, 
which they attributed to dental amalgam restorations, removal of amalgam restora-
tions was followed by a significant reduction of health complaints.
K E Y W O R D S
dental amalgam, dental care, dental materials, humans, prospective studies, subjective health 
complaint
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1  | INTRODUC TION
Dental amalgam is a mixture of metallic mercury and an alloy mainly 
consisting of silver, tin, copper and zinc.1 The mixing ratio between 
mercury and the alloy is approximately 1:1 by weight. Mercury is 
continuously released from the amalgam restorations, absorbed and 
stored in the body, including the brain,2-6 and one of the drawbacks 
of dental amalgam is the potential risk for chronic mercury toxicity.1 
Since almost any protein can be a potential target for mercury, in 
principle, all kinds of adverse effects from mercury exposure could 
be possible.7 The described variability in symptoms and signs from 
elemental mercury vapour exposure could possibly reflect various 
genetic polymorphisms.8
Even though the use of dental amalgam has decreased the last 
decades in favour to polymer-based restorative materials,1,9 a large 
number of people will have amalgam fillings in their teeth for de-
cades ahead, since well-placed dental amalgam restorations usually 
hold for many years.1 In the general population, there is a signifi-
cant concern about potential negative health effects of exposure to 
mercury released from dental amalgam restorations.10 In Norway, 
an estimated 8 per cent of the adult population has had their amal-
gam fillings removed for health reasons only.11 Thus, in 2006 the 
Norwegian Ministry of Health and Care Services initiated a project 
for patients with health complaints, which they attributed to amal-
gam or other dental materials.12 The project included removal of ex-
isting amalgam fillings as experimental treatment, and an evaluation 
of possible changes in health status related to the amalgam removal. 
A study protocol was developed by a task group appointed by the 
Norwegian Directorate of Health. The Dental Biomaterials Adverse 
Reaction Unit, organised at Uni Research AS in Bergen and funded 
by the Ministry of Health and Care Services, was appointed by the 
Norwegian Directorate of Health to implement the project.
Amalgam-attributed health complaints are heterogeneous and a 
variety of symptoms has been attributed to amalgam.13-17 Since the 
symptom pattern is unspecific, amalgam-attributed health complaints 
are difficult to validate and are, for the most part, quantified using 
symptom scales. Notably, amalgam-attributed health complaints are 
largely similar to complaints experienced by patients with so-called 
‘medically unexplained physical symptoms’ (MUPS)18,19 or ‘medically 
unexplained symptoms’ (MUS).20 In order to operationalise and mea-
sure patients’ subjective health complaints, the MUPS concept was ap-
plied to patients who attributed their health problems to amalgam. This 
strategy allowed the comparison to patients suffering from MUPS, 
without symptom attribution to amalgam, in order to control for the 
natural history of health complaints and regression to the mean.
1.1 | Objective of the study
The aim of the present study was to evaluate changes of general 
health complaints after removal of dental amalgam fillings in pa-




The project was designed as a prospective cohort study using a non-
equivalent comparison-group design with pre- and post-test. Three 
groups were recruited separately: The main target group consisted 
of patients with MUPS, which they attributed to dental amalgam 
restorations (Amalgam cohort). Furthermore, these patients ex-
pressed their wish to have their amalgam fillings removed and had to 
fill in and sign an application to participate in the study. Two groups 
served as comparison groups: One primary comparison group of pa-
tients with MUPS recruited from general practice (MUPS cohort), 
and one secondary comparison group of participants, who identified 
themselves as healthy (Healthy cohort). The Healthy cohort was pri-
marily recruited at dental practices. Participants in the comparison 
groups were recruited regardless of amalgam status. The study was 
not purely observational, but quasi-experimental, since patients in 
the Amalgam cohort had to actively apply and fulfil some criteria.
2.2 | Setting
The Dental Biomaterials Adverse Reaction Unit in Bergen organ-
ised the study in collaboration with the Research Unit for General 
Practice in Bergen, both being located at Uni Research Health in 
Bergen, Norway. Several Regional Dental Centers of Competence 
were appointed for the clinical post-treatment examination of pa-
tients in the Amalgam cohort.
2.3 | Participants
Inclusion criteria for all three groups were age between 20 and 
70 years, permanent residence in Norway and ability to comply with 
the protocol. Specific eligibility criteria for each of the three cohorts 
are listed in Table 1, a flowchart and a summary of the recruitment 
procedures are given in Figures 1 and 2. Recruitment period was 
from March 2013 to December 2015. Further details regarding the 
recruitment procedures for the three cohorts are presented in the 
following sections.
2.3.1 | Amalgam cohort
In November 2013, the Directorate of Health sent a letter with 
information about the project to all dentists and general physi-
cians (GPs) in Norway. They were informed about the inclusion 
criteria and that the patients had to be examined according to 
the official guidelines for examination and treatment of patients 
with adverse reactions related to dental materials published by 
the Norwegian Directorate of Health21 prior to inclusion in the 
project. Information was also given via the internet pages of the 
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Directorate of Health (https://helse direk torat et.no/), via arti-
cles and advertisements in the journal of the Norwegian Dental 
Association, and via e-mail sent to members of the Norwegian 
Dental Association. For this project, advertisement in newspapers 
was not deemed appropriate. Detailed information about the pro-
ject, including application forms, was available from the internet 
pages of the project.
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TA B L E  1   (Continued)
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F I G U R E  1   Flowchart showing number of participants
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Patients who had longstanding health complaints attributed to 
dental amalgam fillings, and who were interested to participate in 
the project were instructed to send an application together with 
declarations from the patient's dentist and the patient's general 
practitioner to the study office. The dentist had to declare whether 
the patient was fully examined and treated with regard to oral dis-
eases and conditions, and whether medical conditions and diseases 
were adequately taken care of. The dentist was also asked whether 
the patient's health complaints had lasted for 3 months or longer. In 
addition, we asked for the dentist's assessment (clinical judgment), 
if the patient's dental and medical conditions were likely to deterio-
rate due to participation in the project. The patients were informed 
about potential risks for adverse events associated with the removal 
of amalgam fillings and replacement with new restorative materi-
als.21 The risk for complications (eg, endodontic treatment and ex-
tractions) due to the dental treatment should be low and acceptable, 
as assessed by the dentist (clinical judgment). The dentist should 
also include a treatment plan, dental X-rays, and an estimation of the 
treatment costs to the application.
The declaration from the GP included the following questions: (a) 
Is the patient fully examined with regard to medical conditions and 
are the patient's diseases adequately treated? (b) Have the patient's 
health complaints lasted for 3 months or more? (c) Do you think the 
patient's dental or medical conditions are likely to deteriorate due to 
participation in the project? Actual diagnoses and actual medication 
should be declared as well.
After application of the inclusion and exclusion criteria (Table 1) 
and after having returned the signed informed consent, the patient 
was included in the study (Figure 2). Questionnaire 1 (Q1; baseline) 
was mailed to the patient, and after having returned it to the study 
office the patient was sent a letter with instructions to make an ap-
pointment with his or her GP. The GP was asked to collect a blood 
sample and to complete a short questionnaire about the medical ex-
amination of the patient, diagnoses and prescribed medication the 
last 12 months. A question regarding the GP’s assessment of the 
functional impairment of the patient was also included in the ques-
tionnaire. When the GP’s assessment was received by the study of-
fice and the serum sample was stored in the biobank, the dentist was 
informed that the removal of amalgam fillings could start.
The dental treatment included removal of all visible amalgam 
fillings according to pre-defined procedures.21 Both the dentist and 
the patient completed a diary to document all treatment sessions in 
F I G U R E  2   Timeline for the study. The treatment period (‘Removal of amalgam fillings’) varied in time between the participants
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detail (use of rubber dam during amalgam removal, restorative mate-
rials, local anaesthesia, complications etc).
After completed removal, the patients were examined by a 
dentist affiliated to a Regional Dental Center of Competence or ap-
pointed by the study office. The cost of the dental treatment (amal-
gam removal and replacement with other types of restorations) was 
paid by the project according to pre-defined rules and administered 
by the Regional Dental Centers of Competence.
One year after the last amalgam removal session, a follow-up 
questionnaire (Q2; follow-up) was sent by mail to the patient and the 
patient was asked to make an appointment with the GP for assess-
ment and collection of a blood sample (Figure 2).
2.3.2 | MUPS cohort
Patients in the MUPS cohort were recruited by their family physician/
GP. GPs in two counties in Norway were invited to identify consecu-
tive patients who fulfilled inclusion criteria (Table 1). After a regular 
consultation of the GP, patients who fulfilled criteria were given an 
envelope with written information about the study. Patients who were 
interested to participate in the study (labelled as “Changes of health 
complaints over time”) signed the written informed consent and sent it 
to the study office. Questionnaire 1 (Q1; baseline) was sent to all par-
ticipants who had returned the signed consent form. After completion 
of Q1, the participants received a letter with instructions to make an 
appointment with the GP for collection of a blood sample and to ask 
the GP to complete a short questionnaire about the medical examina-
tion of the patient including an assessment of functional impairment, 
diagnoses and prescribed medication over the last 12 months.
Two years after completion of Q1, a new questionnaire (Q2; fol-
low-up) was mailed and the patient was asked to make an appoint-
ment with the GP for a new assessment and collection of a blood 
sample.
2.3.3 | Healthy cohort
Participants in the Healthy cohort were mainly recruited via dental 
clinics participating in the project and should have no chronic dis-
eases or permanent medication (but intake of vitamins and minerals 
was allowed), they should not be pregnant (or having plans to be-
come pregnant) or breastfeeding (Table 1).
After returning the signed written informed consent, Questionnaire 
1 (Q1; baseline) was mailed to the participants. After returning Q1 to 
the study office, the participants were asked to make an appointment 
with the GP for collection of a blood sample. Two years after comple-
tion Q1, a new questionnaire (Q2; follow-up) was mailed to the par-
ticipants and they were asked to make an appointment with the GP 
for collection of a blood sample. After completion of each question-
naire and having returned it to the study office, the participants in the 
Healthy cohort were sent five lottery tickets (at a total worth of 125 
NOK; approximately 13 €) as compensation for their time.
2.4 | Timeline of the study
The timeline for the study is shown in Figure 1. The duration of amal-
gam removal varied between the participants, but it was anticipated 
that the treatment period, at an average, could last for one year. 
Thus, the follow-up questionnaire (Q2) of the MUPS cohort and the 
Healthy cohort was mailed two years after completion of the first 
questionnaire (Q1). The follow-up period was from June 2015 to 
September 2018.
2.5 | Variables
Primary outcome was the General Health Complaints index (GHC 
index) at 12-month follow-up after completed amalgam removal.16,22 
The GHC index is the sum score of 12 items scored by use of numeric 
rating scales (range 0 to 10) of the following items: Musculoskeletal 
complaints, gastrointestinal complaints, cardiovascular complaints, 
skin problems, complaints related to eyes/sight, complaints re-
lated to ears/hearing/nose/throat, tiredness, dizziness, headaches, 
memory problems, difficulty concentrating and anxiety/depres-
sion. Secondary outcomes were the SF-36 Physical and Mental 
Component Summary scores (SF-36v2 Health Survey; Medical 
Outcomes Trust and QualityMetric Incorporated).
Other secondary outcomes included the Giessen Subjective 
Complaints List (GBB-24, total score), a 50 items symptom list pre-
viously used in the German Amalgam Trial (GAT),23 the Hospital 
Anxiety and Depression Scale (HADS), inorganic mercury in serum, 
cytokine profile, health resource use, sick leave and costs. Results 
from these outcomes will be reported elsewhere.
Potential confounders to be considered were age, gender and 
education. Attribution of health complaints to dental amalgam fill-
ings was considered as a potential effect modifier. In order to obtain 
a quantitative measure of attribution to amalgam, the item ‘Amalgam 
dental fillings’ included in the Modern Health Worries scale24 was 
used. The item was rated by the participants on a five-point scale, 
ranging from 1 (no concern) to 5 (extreme concern). Although being 
represented on an ordinal scale, this variable was included in the 
analysis as approximately interval scaled. In order to assess poten-
tial sources of bias, background variables (age, gender, education, 
civil status, smoking habits and GHC index at baseline) for the main 
target group were compared with the primary comparison group. In 
addition, age, gender, education and baseline value of the outcome 
were included in the adjusted analyses.
2.6 | Data sources
Data were retrieved from questionnaire Q1 and Q2, and from the 
questionnaire completed by the patient's GP after examination. 
Missing data for single items of the GHC index were replaced by 
the cohort mean value for the respective item. If data for more than 
50% of the items were missing, the sum score was coded as ‘missing’.
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2.7 | Sample size and power calculations
Using data from a previous study22 the following initial assumptions 
were made: (a) A mean difference in GHC-index score for general 
health complaints of 5.0 between the amalgam cohort and the 
MUPS cohort (corresponding to a mean difference before–after of 
10.0 in the amalgam group versus a mean difference of 5.0 in the 
MUPS cohort). (b) A common within-group standard deviation of 
10.0. Based on these assumptions and with criterion for significance 
(alpha) = 0.05 with two-tailed tests, a sample size of 100 patients in 
the amalgam cohort and 50 patients in the MUPS cohort would give 
the study a power of 82% to yield a statistically significant result. 
Based on a more realistic ratio of the group sizes of 1:1 for amalgam 
and MUPS cohorts, a secondary power analysis showed a similar 
power of 83% for a total of 60 patients given a mean difference of 
2.5 in the MUPS cohort (means a between-group difference of 7.5 in 
GHC change scores with all other assumptions identical).
2.8 | Quantitative variables
Continuous variables were presented as mean values with standard 
deviation (SD) and in box-plots indicating median, percentiles, max 
and min values. In addition, 95% confidence intervals for mean val-
ues were presented when appropriate. Categorical variables were 
presented as frequencies.
2.9 | Statistical methods
The statistical model was built upon the pre-defined null-hypoth-
esis that there were no differences between the Amalgam cohort 
and the MUPS cohort with respect to the change scores for the 
primary outcome variable. Statistical testing of potential differ-
ences between the groups was performed by analysis of variance 
complemented by an adjustment for covariates (baseline value of 
the primary change score, age, gender and education).25 In addition, 
predictors of change of the primary outcome measure at follow-up 
were subject to multivariate analysis including the potential effect 
modifier. The comparison between treatment group and comparison 
group included only patients who responded to the follow-up ques-
tionnaire (per-protocol analysis). When appropriate, P-values were 
adjusted for multiple comparisons using the Bonferroni correction. 
Analyses were performed using IBM-SPSS (IBM Corp. IBM SPSS 
Statistics for Windows, version 25, Armonk, NY, USA).
2.10 | Ethical aspects
The study was approved by the local research ethics committee 
(REK2012/331) and registered at ClinicalTrials.gov (https://clini 
caltr ials.gov/ct2/show/NCT01 682278; NCT01682278). A stop 
group was appointed consisting of the Advisory Board of the Dental 
Biomaterials Adverse Reaction Unit. In addition, a Scientific Advisory 
Board was assigned to the study.
2.11 | Patient involvement
In the planning phase of the study, the patient organisation 
Forbundet Tenner og Helse (FTH; http://ffo.no/Medle msorg anisa 
sjone r/F/Forbu ndet-Tenner-og-Helse/) participated at repeated 
meetings with the study protocol task group to discuss and give 
comments to the study protocol. In addition, representatives from 




A total of 129 subjects (n = 49, n = 52 and n = 28 in the Amalgam, 
MUPS and Healthy cohorts, respectively) were recruited and signed 
informed consent; n = 95 subjects (n = 37, n = 33, n = 25) fulfilled 
all eligibility criteria, adhered to all protocol specifications for enrol-
ment and were included in the study; and n = 79 (n = 32, n = 28, 
n = 19) were available for follow-up analysis (Figure 1). Further de-
tails about each group are presented in the following sections.
3.1.1 | Amalgam cohort
Between August 2013 and December 2015, 59 individuals sent an 
application for removal of all amalgam fillings as experimental treat-
ment. Of these, 49 fulfilled inclusion criteria (Figure 1) and signed 
the written informed consent form. Questionnaire 1 (Q1) was sent 
and returned by all 49 participants (Figure 1). The questionnaire 
completed by the GP regarding the general health of the participant 
was returned for 46 participants. MUPS criteria were fulfilled by 37 
patients in the amalgam group (Table 2).
Removal of amalgam restorations was started for all 37 patients 
in the amalgam cohort. One patient terminated her participation due 
to health reasons and four patients had to be excluded for different 
reasons (Table S1). Thirty-two patients in the amalgam cohort fin-
ished the dental treatment and completed Questionnaire 2 (Q2) one 
year after the last treatment session (Figure 1).
3.1.2 | MUPS cohort
In the period March 2013 to January 2015, 52 patients accepted 
to participate and signed the written informed consent form. 
Questionnaire 1 was sent by mail to all of these, and 44 patients 
completed the questionnaire, and sent it back to the study office 
(Figure 1). The questionnaire to the GP regarding the patient's 
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health was returned for 39 patients. After assessment by the pa-
tient's GP, the MUPS criteria were applied. Thirty-three patients 
fulfilled the criteria and were included in the MUPS cohort. Two 
years later, Questionnaire 2 was mailed and returned by 28 pa-
tients in the MUPS cohort (Figure 1). In the baseline questionnaire, 
section ‘What do you think could be the reason for your health 
complaints?’, no patients in the MUPS cohort listed ‘amalgam fill-
ings’ or ‘mercury from amalgam fillings’ as a possible cause of their 
health complaints.
3.1.3 | Healthy cohort
Thirty-one potential participants were recruited between March 
2014 and March 2016 and received a consent form. Of these, 28 re-
turned the signed informed form and 25 responded to Questionnaire 
1 (Figure 1). In the Healthy cohort, 19 participants completed 
Questionnaire 2 two years after completion of Questionnaire 1.
3.2 | Baseline characteristics
The proportion of women was much higher in the MUPS cohort 
(88%) than in the amalgam cohort (60%) and the healthy cohort 
(68%). The distribution of age, civil status and smoking habits did 
not differ significantly, but gender and education were not equally 
distributed between the cohorts (Fishers exact test; P = .024 and 
P = .004, respectively) (Table 2).
At baseline, the GHC index was highest in the Amalgam cohort 
(mean 42; Table 2). In the MUPS cohort and in the Healthy cohort, 
the mean values were lower (mean values 35, and 10, respectively). 
The mean baseline value in the Amalgam cohort and in the MUPS 
TA B L E  2   Demographics, baseline data
Cohort
Amalgam 
(n = 37) MUPS (n = 33)
Healthy 
(n = 25)
Female gender, n (%) 22 (59) 29 (88) 17 (68)
Age (years); mean (SD) 51.0 (7.9) 48.6 (10.4) 46.7 (12.8)
Education a , n (%)
Primary and lower secondary school 3 (8.1) 4 (12.1) 0 (0)
Upper secondary school, vocational program 10 (27.0) 9 (27.3) 1 (4.0)
Upper secondary school, general program 4 (10.8) 9 (27.3) 6 (24.0)
Higher education (less than 4 years) 11 (29.7) 9 (27.3) 6 (24.0)
Higher education (4 years or more) 9 (24.3) 2 (6.1) 12 (48.0)
Civil status, n (%)
Married 24 (64.9) 22 (66.7) 12 (48.0)
Cohabitation 6 (16.2) 5 (15.2) 7 (28.0)
Single 3 (8.1) 5 (15.2) 4 (16.0)
Divorced 4 (10.8) 1 (3.0) 2 (8.0)
Household yearly income; median group
1000 NOK 550-750 550-750 >1000
Smoking habits, n (%)
No, never ever 15 (40.5) 17 (51.5) 14 (56.0)
No, stopped less than one year ago 1 (2.7) 2 (6.1) 0 (0.0)
No, stopped more than one year ago 16 (43.2) 6 (18.2) 6 (24.0)
Yes, but not daily 0 (0) 3 (9.1) 3 (12.0)
Yes, daily 5 (13.5) 3 (9.1) 2 (8.0)
Missing data 0 (0) 2 (6.1) 0 (0)
Sick leave/sickness benefits, n (%) 24 (64.9) 21 (63.6) 1 (4.0)
GHC; mean (SD) 42.4 (17.4) 35.4 (14.6) 10.5 (14.0)
SF-36 Physical Component Summary; mean (SD) 35.3 (9.3) 37.3 (8.0) 54.3 (4.8)
SF-36 Mental Component Summary; mean (SD) 45.7 (9.2) 47.8 (11.1) 53.9 (5.8)
Worry about risk for personal health—Dental amalgam fillingsb ; mean (SD) 3.6 (0.9) 2.2 (1.2) 1.5 (1.0)
aFor definitions, see Ref 36 
bItem from Modern Health Worries24 coded from 1 (no concern) to 5 (extreme concern). 
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cohort was not significantly different (P = .197), but the mean 
value in the Healthy cohort was considerably lower compared with 
the other groups (P < .001). The baseline values for SF-36 Physical 
Component Summary and SF-36 Mental Component Summary 
scores followed a similar pattern; the Amalgam cohort and the 
MUPS cohort were not significantly different, but the mean values 
in the Healthy cohort were considerably higher compared with the 
other groups (Table 2). Amalgam cohort patients were more wor-
ried about the risk for the personal health associated with dental 
amalgam fillings compared with patients in the MUPS (P < .001) 
and Healthy cohorts (P < .001; Bonferroni adjusted p-values; 
Table 2).
At baseline, mean values of each of the 12 items included in the 
GHC index did not differ significantly between the Amalgam cohort 
and the MUPS cohort, except for symptoms related to ear/nose/
throat (Bonferroni adjusted P = .013; Figure S1).
The proportion of patients on sick leave or receiving other sick-
ness benefits was similar in the Amalgam cohort and in the MUSP 
cohort (64.9% and 63.6%, respectively). Household income was also 
similar in the two groups (Table 2, Figure S2). There were no major 
differences between the groups regarding household type (Figure 
S3).
3.3 | Main results
From baseline to follow-up, the GHC index was significantly reduced 
in the Amalgam cohort, (P < .001), while no significant change was 
observed for the MUPS or Healthy cohorts (Table 3). The GHC-index 
change score (GHC index at Q1 minus GHC index at Q2) was sig-
nificantly higher in the Amalgam cohort (mean 12.8, SD 15.9) com-
pared with the MUPS cohort (mean 1.2, SD 12.3; P = .004, Table 3), 
TA B L E  3   General Health Complaints index score and SF-36 Physical and Mental Component Summary at baseline (Q1), at follow-up (Q2) 
and change score (baseline minus follow-up)
Group
Amalgam cohort (n = 32) MUPS cohort (n = 28a ) Healthy cohort (n = 19)
Mean SD P-valueb  Mean SD P-valueb  Mean SD
P-
valueb 
GHC at baseline (Q1) 43.3 c  17.8 36.6 c  14.2 10.0 15.0
GHC at follow-up (Q2) 30.5 c  14.4 35.4 c  19.2 9.1 9.4
























−4.3 8.7 0.009 −1.5 10.4 0.449 −0.4 5.2 0.711
Note: Mean values and standard deviations (SD) are given. P-values were adjusted for all pairwise comparisons within a row using the Bonferroni 
correction.
an = 27 for SF-36 Physical Component Summary and Mental Component Summary. 
bP-value for within-group test of change between Q1 and Q2 (H0: change score = 0). 
cSignificantly different from Healthy cohort (P < .001). 
dSignificantly different from MUPS cohort (P = .004). 
eSignificantly different from Healthy cohort (P = .009). 
fSignificantly different from Amalgam cohort and MUPS cohort (P < .001). 
gSignificantly different from Amalgam cohort (P = .004). 
hSignificantly different from Amalgam cohort (P = .005). 
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indicating more symptom reduction in the Amalgam cohort. In 
Figure 3, box-plots show data from Q1 and Q2 for participants with 
observations at both baseline and follow-up.
After adjustment for covariates (gender, age, education and 
baseline GHC index), the mean difference in GHC-index change 
score between the Amalgam cohort and the MUPS cohort was −8.0 
(95% confidence interval from −15.4 to −0.5; P = .036, Table S2).
3.4 | Other analyses - Secondary outcomes
From baseline to follow-up, the SF 36 Physical and Mental 
Component Summary scores increased significantly in the Amalgam 
cohort (P = .001 and P = .009, respectively), indicating improved 
health status. In the MUPS cohort and the Healthy cohort, there 
were no significant changes from baseline to follow-up (Table 3, 
Figures S5 and S6).
The change score of SF 36 Physical Component Summary in the 
Amalgam cohort (mean −5.1, SD 7.9) was significantly larger com-
pared with the MUPS cohort (mean 0.9, SD 7.1; P = .004; Table 3) 
indicating more improvement in the Amalgam cohort. The SF-36 
Mental Component change score was not significantly different 
between the Amalgam (mean −4.3, SD 8.7) and the MUPS cohorts 
(mean −1.5, SD 10.4; P = .682, Table 3). The mean adjusted differ-
ence between amalgam cohort and MUPS cohort for SF 36 Physical 
Component Summary was 5.9 (95% confidence interval from 1.5 to 
10.3, P = .009, Table S2).
3.5 | Supplementary analyses of the 
Amalgam cohort
For the Amalgam cohort, predictors of change of the GHC index 
at follow-up were analysed in models without (Model 1) and with 
(Model 3) the potential effect modifier (item ‘Amalgam fillings’ from 
the Modern Health Worries questionnaire), which also was analysed 
separately (Model 2). Significant effects were found for GHC index 
at baseline (P < .001) and for education (Model 1 and 3, Table S3; 
Figure S4). Participants with higher education had significantly more 
improvement as measured by the GHC index.
In corresponding analyses of potential predictors of change 
at follow-up for SF-36 Physical Component Summary and Mental 
Component Summary scores, none of the variables included in 
the model were significant predictors, except the SF-36 Mental 
Component Summary at baseline (Model 1 and 3, Table S3). The 
potential effect modifier ‘Amalgam dental fillings’ from the Modern 
Health Worries scale was not significant in any of the models 
(Table S3).
Exploratory post hoc analyses of the change of separate GHC items 
showed that the mean values of all items decreased after removal of 
amalgam restorations. The decrease was statistically significant for 
all but three items (symptoms from ear/nose/throat, headache and 
gastrointestinal symptoms). Reductions by more than one unit were 
observed for the items difficult to concentrate, anxiety/depression, 
pain from muscles and joints, fatigue, cardiovascular symptoms, mem-
ory problems and dizziness. Thus, the response was more general, and 
therefore best described by the GHC summary score.
3.6 | Analysis of participants lost to follow-up
In the Amalgam cohort, four patients were excluded (Table S1) and 
one patient terminated participation due to health reasons. In the 
MUPS cohort and in the Healthy cohort, 11 participants did not 
respond to the follow-up questionnaire (Q2; Figure 1). The mean 
baseline GHC index for these was 36.9 (SD 15.9), 28.9 (SD 16.8) and 




The main finding of this study was that the intensity of general health 
complaints decreased after removal of dental amalgam fillings in pa-
tients with MUPS who attributed their health complaints to amal-
gam fillings. The comparison group showed similar health complaints 
(as measured with the GHC index), and no change was observed over 
time. In addition, the SF-36 Physical and Mental Summary scores 
increased significantly after removal of amalgam fillings, indicating 
better health after amalgam removal.
F I G U R E  3   General Health Complaints index score at baseline 
(Q1) and at follow-up (Q2) for participants with data from both 
baseline and follow-up. The boxplot indicates the median (the line 
across the box), quartiles (box edges) and extreme values. The 
highest and lowest values are indicated by the lines that extend 
from the upper and lower edge of the box or (if defined as outliers) 
indicated with circles or stars
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4.2 | Strengths and Limitations
To our knowledge, this is the first study of amalgam removal focus-
ing on patients with MUPS with or without symptom attribution to 
dental amalgam fillings. Strengths of the study include an independ-
ent dental follow-up examination of patients after amalgam removal, 
a comprehensive outcome assessment including the most com-
mon symptoms in the patient group (GHC index, Munich Amalgam 
Checklist) as well as generic quality of life (SF-36), and a follow-up 
duration sufficient to mirror symptom changes after amalgam re-
moval, as observed in previous studies. In addition, a long-term fol-
low-up five-year after amalgam removal is planned.
The study was initiated by Norwegian health authorities as part 
of a treatment project for patients with health complaints attributed 
to dental materials (amalgam). Because of the specific framework 
of the treatment project, including ethical concerns, a randomised 
control design was not deemed feasible. In this context, the MUPS 
concept was used to operationalise the comparison between pa-
tients with health complaints attributed to amalgam and patients 
with similar health complaints but without attribution to amalgam, 
thus allowing for a prospective comparison matched for symptoms.
Blinding of the treatment was also not possible. Thus, expec-
tations about the treatment effects could influence the results. 
However, the improvement of health after amalgam removal is re-
ported to last for many years,26-28 which may reduce the probabil-
ity of placebo as the only cause of the improvement. The possibility 
of a discontinuation of a hypothetical nocebo effect from amalgam 
fillings has been suggested as one potential explanation for a reduc-
tion of health complaints following amalgam removal.22 Another 
possibility is observation bias, since the symptom and quality of life 
outcomes are documented by self-report, and patients offered the 
desired treatment free of charge could possibly exaggerate their im-
provement. However, symptom reduction after amalgam removal 
has been reported to be associated with the reduction of concentra-
tion of inorganic mercury in serum29 as well as the concentration of 
mercury in urine at baseline before treatment.27,29 Such associations 
between symptoms and laboratory parameters cannot be observed 
by the patients, which makes observation bias an unlikely expla-
nation for the improvements. Regression to the mean and natural 
recovery can also contribute to symptom reduction; however, the 
MUPS cohort with similar symptoms at baseline had no improve-
ment. Admittedly, baseline GHC scores were higher in the Amalgam 
cohort (mean 43.3) than in the MUPS cohorts (36.6), thus leaving 
more room for improvement. However, the outcome difference in 
favour of the Amalgam cohort remained significant after adjustment 
for baseline scores as well as demographics, even though the pre-de-
fined sample size of the study was not met.
4.3 | Interpretation
The study provides additional evidence of reduction of health com-
plaints in patients with attribution of health complaints to amalgam 
after amalgam removal. Since neither blinding nor placebo control 
was used, the observed reduction of the intensity of general health 
complaints can be interpreted as an effect from both specific and 
non-specific treatment effects. A reduction of health complaints is 
in agreement with data from previous controlled studies22,23,26,30 
and studies without comparison groups.28,31 In cross-sectional 
studies of large cohorts, people with many amalgam fillings did 
not have more symptoms or diagnosed diseases than people with 
few fillings.32-34 Thus, the findings that patients with health com-
plaints attributed to amalgam and who have their amalgam fillings 
removed report lower intensity of health complaints after amal-
gam removal could seem contradictory. However, a relatively low 
prevalence of health complaints attributed to amalgam fillings in 
the general population and a relatively low correlation between 
number of amalgam fillings and health complaints in the patient 
group could be of importance and explain the seemingly conflict-
ing results.
In the present study, we used both the GHC index, which is de-
signed to monitor health complaints attributed to amalgam, and the 
generic SF-36 questionnaire. Both showed significant improvement 
of health. As a rule of thumb, a change score of a half standard devi-
ation is considered a clinically meaningful difference.35 Thus, a mean 
increase of 5 points of the SF-36 Physical Component scale (SD = 10 
points) in the Amalgam group indicates a marked improvement in 
physically oriented quality of life after removal of amalgam fillings.
4.4 | Generalisability
Since we used inclusion and exclusion criteria of the participants in 
this study, the external validity is limited to patients who have MUPS 
attributed to their amalgam fillings and fulfilling the criteria. All pa-
tients included in the Amalgam cohort were examined both by the 
patients’ GP and the patient's dentist. Both assessed that there was 
no major risk for deterioration of the health of the patient if they 
participated in the project. Thus, this is an important limitation and 
must be considered in relation to the generalisability of the results 
from the study.
5  | CONCLUSION
This study supports the hypothesis that MUPS attributed to amal-
gam fillings, as present in our participants in the Amalgam group, are 
reduced after removal of amalgam fillings in patients fulfilling the 
criteria used in this study.
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